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MEDICAL IMPLICATIONS OF THE GENETIC REVOLUTION*
MONIQUE K. MANSOURA, PH.D.** "
FRANCIS S. COLLINS, M.D., PH.D.***
I. THE HUMAN GENOME PROJECT: ITS PROMISE AND CHALLENGES
The Human Genome Project (HGP), the multi-disciplinary,
multi-institutional, multi-million dollar effort aimed at mapping and
sequencing the entire three billion base pairs, of the human genome,1
will be completed in less than a decade. 2 A primary imp'etus of this
monumental task, which has mobilized the efforts of thousands of
scientists and generated the enthusiastic support of Congress, is to
provide the biomedical research community with the tools to identify
1.!
* The ideas and opinions expressed in this paper are those of the authors' only and
do not represent any position or policy of any federal agency, or any other institution or
organization to which they are affiliated.
** Postdoctoral Fellow in the laboratory of Dr. Melissa Ashlock at the National Human
Genome Research Institute, where she conducts research in the field of cystic fibrosis. Dr.
Mansoura received her M.S. in Human Genetics (1992) and Ph.D. in Biomedical Engineer-
ing (1996) from the University of Michigan where she was awarded a National Science
Foundation Graduate Fellowship. The author wishes to thank Lorry Brody, Ph.D., David
FitzGerald, Ph.D., and Larry Fenner, Ph.D. for their critical reviews of this manuscript and
the insightful discussions.
*** Director of the National Human Genome Research Institute at the National Insti-
tutes of Health (NIH). Dr. Collins oversees a fifteen year project directed at mapping and
sequencing all of the human genes. He joined NIH in 1993 after serving as a member of
the faculty at the University of Michigan and completing a fellowship in human genetics at
Yale. His research led to the identification of genes responsible for cystic fibrosis,
neurofibromatosis and Huntington's disease. He is a member of the Institute of Medicine
in the National Academy of Sciences.
1. "Within the nucleus of every human somatic cell, in two versions distributed over
23 chromosomes [one set maternally derived, and the other paternally derived], lies a
genetic instruction tape embodied in DNA [deoxyribonucleic acid]." See Francis S. Collins,
Sequencing the Human Genome, 32 Hosp. PRAc. 35, 35 (1997). Each set of chromosomes
contains three billion bits of information, genetic sequence data, spelled out in a four
letter code. See id. Each cell uses this information to create the proteins which do the work
necessary to carry out the functions of that particular cell type. See id. "[T]he sequence, is
99.9% identical from one individual to another. This makes it reasonable to speak of a
human genome, at least for the purposes of determining a complete representative se-
quence. .. ." Id.
2. See id; National Human Genome Research Institute, National Institutes of Health
(visited Jan. 14, 1998) <http://www.nhgri.nih.gov/HGP/>. Two recent reviews also pro-
vide an overview of the HGP. See generally Leslie Fink & Francis S. Collins, The Human
Genome Project: View from the National Institutes of Health, 52 J. AM. MED. WOMEN'S Assoc. 4, 4-
7 (1997); Ani Patrinos & Daniel W. Drell, The Human Genome Project: View From the Depart-
ment of Energy, 52. J. AM. MED. WOMEN'S AsSOC. 8 (1997).
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the molecular basis of virtually all diseases, so that ultimately this in-
formation can be used by scientists and physicians to provide early
detection and to develop and evaluate treatment strategies and cures
for affected individuals. Since genetic predisposition plays an impor-
tant role in almost every disease, albeit to widely varying degrees, the
HGP promises to have a significant medical benefit for everyone.
However, the promise of the HGP is tempered by concern about the
potential misuses of genetic information. Fear of discrimination by
insurers and employers has already limited some potential benefits as
some individuals are refusing to participate in research and declining
testing for fear of discrimination and loss of privacy.' Similarly, the
improper use of genetic information in legal contexts threatens the
realization of the full medical benefit of the science.4 This has united
patient advocacy groups, such as the National Action Plan on Breast
Cancer (NAPBC), and researchers at the National Human Genome
Research Institute (NHGRI) in efforts to prevent such misuse.5
By all scientific measures the HGP has been a resounding success
thus far.6 The exponential rate at which maps and technologies have
been created and new genomic sequences are being deposited into
Genbank7 is having a significant impact on the identification of the
molecular basis of genetic diseases - an early, but invaluable step in
the path to understanding the underlying pathophysiology and devel-
oping treatments and cures. Current estimates indicate that a new
gene is identified and entered into the database every 2.5 days.8 As an
example of the accelerated rate of gene discovery, it is insightful to
compare efforts of gene hunting by positional cloning' before and
3. See infra notes 70-109 and accompanying text.
4. See id.
5. The Hereditary Susceptibility Working Group of the NAPBC has made this topic a
major focus of interest. The Hereditary Susceptibility Working Group, The National Ac-
tion Plan on Breast Cancer (last modified Jan. 8, 1997) <http://www.napbc.org/napbc/
heredita.htm>.
6. Francis S. Collins & David Galas, A New Five-Year Plan for the US. Human Genome
Project, 262 SCIENCE 43, 43, 46 (1993).
7. GenBank is the NIH genetic sequence database, an annotated collection of all pub-
licly available DNA sequences. There are approximately 1,053,500,000 bases in 1,766,000
sequence records as of October 1997. National Center for Biotechnology Information,
(last modified Oct. 20, 1997) <http://www.ncbi.nlm.nih.gov/Web/Genbank/index.html>.
8. Mark Boguski, Lecture at the National Institute of Health on Current Topics in
Genome Analysis (Nov. 4, 1997).
9. Positional cloning is the method of locating a gene based on its position in the
genome without necessitating knowledge of the functional product. See Soumitra Ghosh &
Francis S. Collins, The Geneticist's Approach to Complex Disease, 47 ANN. REv. MED. 335 (1996).
It depends upon linkage analysis in which a DNA marker identifying a particular location
within the genome is found to cosegregate with disease in one or more families. See id. If
such a marker is identified, it indicates that the altered genetic sequence involved in the
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after the HGP was initiated. The cystic fibrosis (CF) gene was identi-
fied in 1989, before the HGP was formally initiated, after an arduous
ten-year collaborative effort with an overall expense of roughly fifty
million dollars. In striking contrast, the gene abnormality that causes
some cases of Parkinson's disease was identified in 1997 within only
nine days.1" Using samples collected from a large family with a high
incidence of Parkinson's, researchers at the NHGRI obtained linkage
to a region of the genome containing approximately 100 genes. One
of the genes already placed in this interval was alpha-synuclein, which
was an excellent candidate for being a Parkinson's disease gene, and
was found to harbor a subtle mutation in the Parkinson's disease fami-
lies."1 As the HGP reaches fruition, this accelerated path to gene dis-
covery will be the rule rather than the exception.
What value does the identification of a genetic basis of disease
have for an individual and their family? It is the goal of this paper to
delineate the role that genetic information plays in the onset of ge-
netic disease and to identify the potential medical implications for an
individual and for family members. The link between a sequence al-
teration in the genome of an individual and the possibility of future
disease is complex and poorly understood in all but a few cases. A
review of the fundamental principles of genetics and an update on the
realities of what the science can offer ensures a solid foundation for
ethical discussions and legal debates. Potential negative conse-
quences of the misuse of genetic information and the depth of the
impact it may have on the lives of individuals and their families de-
mands that any discussion be grounded in scientifically-based analy-
ses. We must be cognizant that we are dealing with a continuously
expanding base of information and be aware of new discoveries which
may inform our deliberations. We should also challenge ourselves to
attempt to foresee the technologies and discoveries that lie ahead in
order to minimize unnecessary burdens on future generations. A re-
cent editorial in Science discussing the breakthroughs of 1997 states
that
disease is "linked," or nearby, in genetic terms. See id.; see also Francis S. Collins, Of Needles
and Haystacks: Finding Human Disease Genes by Positional Cloning, 39 CLINICAL RFs. 615
(1991) (detailing information about the positional cloning strategy); Francis S. Collins,
Positional Cloning Moves From Perditional to Traditional, 9 NATURE GENETICS 347 (1995).
10. See Mihael H. Polymeropoulos et al., Mutation in the Alpha-Synuclein Gene Identified in
Families with Parkinson's Disease, 276 SCIENCE 2045 (1997); see also generally Robert L. Nuss-
baum and Mihael H. Polymeropoulos, Genetics of Parkinson's Disease, 6 HUM. MOLECULAR
GENETICS 1687 (1997).
11. See NHGRI Media Release: Parkinson's Disease (visited Feb. 6, 1998)
<http:www.nhgri.gov/DIR/LGDR/PARK2/audio.html>.
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[I]ike the 4-minute mile, which was once believed to be the
limit of human running capacity, preconceived limits in sev-
eral scientific fields were made obsolete this year .... This
year's advances demonstrate once again that one should
never say never in science and that the exercise of imagining
what could come to pass may be worth practicing. 12
A. Molecular Basis of Genetic Disease
Genetic diseases result from a sequence alteration in one or more
genes and can be classified into three major categories: chromosomal,
single gene (monogenic) and polygenic. 13 In many instances, the oc-
currence of the disease results from a combination of genetic and en-
vironmental factors - that is, genetic alterations are frequently
predisposing, not predetermining, and require additional triggers. We
need to challenge genetic reductionism, the philosophy that all dis-
eases, traits, and behaviors are determined solely by our genetic
constitution.
Chromosomal disorders are the result of the addition or deletion
of parts of entire chromosomes and are typically identified using cyto-
genetic techniques. Recent technological advances in spectral kary-
otyping 4 are significantly improving the sensitivity of detection of
these abnormalities. Monogenic and polygenic disorders involve al-
terations in one or more genes, respectively. These alterations can
occur in a variety of ways including insertions, deletions, or substitu-
tions of one or more base pairs. For monogenic diseases it is not unu-
sual for "a minute genotypic difference [to] have profound
phenotypic effects. A classic example is sickle-cell anemia, in which
precisely one A (the nucleotide, or base, adenine), among three bil-
lion code letters, has been replaced by a T (thymine), affecting the
instructions for [3 globin."' 5 More recent examples include cystic fi-
brosis16 and achondroplasia,17 the most common type of short-limbed
dwarfism. Still, identification of a gene mutation associated with an
12. Floyd E. Bloom, Breakthroughs 1997, 278 SCIENCE 2029, 2029 (1997).
13. See THoMAS D. GELEHRTER ET AL., PRINCIPLES OF MEDICAL GENETICS 3 (2d. ed. 1998).
14. Spectral karyotyping is a technique which uses multicolor fluorescent dyes and
spectral imaging to simultaneously distinguish each human chromosome by a different
color. See Evelin Schrrck et al., Multicolor Spectral Karyotyping of Human Chromosomes, 273
SCIENCE 494 (1996) (initial report describing this new cytogenetic technique); see also Tim
Veldman et al., Hidden Chromosome Abnormalities in Haematological Malignancies Detected by
Multicolour Spectral Karyotyping, 15 NATURE GENETICS 406 (1997).
15. Collins, supra note 1, at 35; see GELEHRTER ET AL., supra note 13, at 98 (discussing
further the consequences of this genetic mutation).
16. See generally John R. Riordan et al., Identification of the Cystic Fibrosis Gene: Cloning and
Characterization of Complementary DNA, 245 SCIENCE 1066, 1066 (1989).
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inherited disorder, while significant, is only an early step in the eluci-
dation of the pathophysiology and the development of treatments
and/or cures (Figure 1).18
Figure 1 - Patterns of progress in genetic medicine show the influence the
Human Genome Project is having on overall rates of discovery
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17. See Rita Shiang et al., Mutations in the Transmembrane Domain of FGFR3 Cause the Most
Common Genetic Form of Dwarfism, Achondroplasia, 78 CELL 335, 335 (1994).
18. Figure one adapted from Collins, supra note 1, at 36.
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The consequence of the sequence alteration in the gene is often
the aberrant regulation and/or function of the encoded protein.19
Understanding the physiological role of the encoded protein is often
critical to the development of treatments and cures. However, the
promise of gene therapy offers a means to use the gene as a therapeu-
tic agent, and perhaps bypass acquiring detailed knowledge of the un-
derlying pathophysiology of the disorder (Figure 1). Most likely, as
has been the situation for cystic fibrosis, scientists will pursue in paral-
lel both gene therapy and traditional pharmacological approaches
and a combination of treatment strategies will be applied to improve
the quality of life of affected individuals.
B. Genetic Testing: Goals, Methods, and Limitations
All of us carry an estimated five to fifty significant genetic altera-
tions. Genetic disease should not be thought of as the unfortunate
fate of relatively few individuals who have been affected by rare inher-
ited disorders. With our rapidly expanding understanding of the role
of genes in common disorders such as many forms of cancer, heart
disease, diabetes, mental illness, it seems more likely that in the fu-
ture virtually all of our lives will be touched by the genetic revolution.
Genetic testing is the means which allows such sequence alterations to
be identified. In a clinical context, genetic testing is applied in several
settings. The first widespread application has been in prenatal diag-
nosis where chromosomal abnormalities or specific mutations in
known genes are tested for. This may be in the context of advanced
maternal age (looking for Down syndrome) or the test may be more
specific if one or both of the partners has a family history of a genetic
disease such as cystic fibrosis (CF).
Genetic testing is also carried out to assist the diagnosis of disease
for individuals who are currently ill, such as a DNA or cytogenetic test
to look for fragile X syndrome2" in a mentally retarded male. The
newest area, but one in which we anticipate the greatest growth, is that
of pre-symptomatic diagnosis - identifying individual risks of future ill-
ness in individuals who are currently healthy. It is this predictive ca-
pacity which sets this kind of genetic information apart from most
19. See generally Mahlon Hoagland & Bert Dodson, The Molecules of Life, 36JunGEs'J. 11
(1997) (providing an informative lay discussion of the relationship between DNA and
proteins).
20. See Lisa Chakrabarti & Kay E. Davies, Fragile X Syndrome, 10 CURRENT OPINION IN
NEUROLOGY 142 (1997) (identifying that the Fragile X Syndrome is the single most com-
mon form of inherited mental handicap after Down's Syndrome, and the known cognitive
dysfunction in Fragile X males includes visual-spatial abilities, deficits in short-term mem-
ory, visual-motor coordination, processing of sequential information, and attention).
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other medical information, and is one of the unique features which
justifies increased surveillance of clinical utility and the development
of policies/legislation to minimize abuse. One consequence of this
predictive capacity has been described as a "therapeutic gap."21  This
situation arises when a disease can be diagnosed or predicted by ge-
netic testing, yet no effective interventions are available to improve
the outcome. Unfortunately, this is today's reality for most inherited
diseases. The agonizing dilemmas this poses have been eloquently ad-
dressed by Dr. Nancy Wexler, primarily in the context of genetic test-
ing for Huntington's disease (HD).22 She has also displayed
remarkably accurate foresight in the discussion of the development of
genetic tests for breast cancer, colon cancer, heart disease, and
Alzheimer's disease.23
In addition to the therapeutic gap, there are two other significant
uncertainties which arise from the underlying complexity of genetic
disease and thereby limits the value of predictive genetic test informa-
tion. "Negative (normal) test results might not rule out future occur-
rence of the disease. . . . A positive test result might not mean the
disease will inevitably develop ' 24 and often offers little information to
the individual regarding when disease onset will occur, and/or how
severe the expression of the disease will be.25
C. Underlying Complexity of Genetic Disease
Diagnosis of genetic diseases is often complicated by a number of
factors which result in considerable clinical (phenotypic) heterogene-
ity.26 "Clinical heterogeneity" refers to the variability in expression of
a particular disease among those affected (e.g., the age of onset, the
extent and severity of symptoms, impact on morbidity/mortality).
21. TASK FORCE ON GENETIC TESTING, NATIONAL INSTITUTES OF HEALTH - DEPARTMENT
OF ENERGY, PROMOTING SAFE AND EFFECTIVE GENETIC TESTING IN THE UNITED STATES 2-3
(Neil A. Holtzman & Michael S. Watson eds., 1997) [hereinafter PROMOTING SAFE AND
EFFECTIvE GENETIC TESTING].
22. See Nancy Wexler, Clairvoyance and Caution: Repercussions from the Human Genome
Project, in THE CODE OF CODES: SCIENTIFIC AND SOCIAL ISSUES IN THE HUMAN GENOME PRO-
JECT 211, 223 (Daniel J. Kevles & Leroy Hood, eds. 1992).
23. See id. at 242.
24. See PROMOTING SAFE AND EFFECTIVE GENETIC TESTING, supra note 21, at 3.
25. See id. Other factors such as analytical validity, while critical to the accuracy of a
genetic test result, will not be discussed here. Details can be found in the Final Report of
the Task Force on Genetic Testing. See id.
26. See Ulrich Wolf, The Genetic Contribution to the Phenotype, 95 HuM. GENETICS 127, 129
(1995); Ulrich Wolf, Identical Mutations and Phenotypic Variation, 100 HUM. GENETICS 305,
316 (1997). See generally Eric R. Fearon, Human Cancer Syndromes: Clues to the Origin and
Nature of Cancer, 278 SCIENCE 1043, 1048 (1997).
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The relationships between alterations in genetic sequences27 and
their clinical manifestations are most often complex and unpredict-
able, even in conditions with Mendelian 28 patterns of inheritance. 29
Realizing this daunting complexity, it is nonetheless appropriate to
say that in many cases, beneficial information can be obtained by ge-
netic testing, though what constitutes 'beneficial' is a highly individu-
alistic determination.
In an effort to dissect clinical heterogeneity, and thus, the uncer-
tainty that underlies the diagnosis/prognosis of genetic disorders, we
will review each of the contributing factors. The first underlying
source of phenotypic heterogeneity is genetic heterogeneity. This reflects
the fact that different mutations in different genes can cause an iden-
tical or similar phenotype. ° Genetic heterogeneity can be classified
into two major categories: allelic heterogeneity and locus heterogeneity (Fig-
ure 2).31
Figure 2 : Underlying sources of genetic heterogeneity
ALLELIC HETEROGENEITY LOCUS HETEROGENEITY
one gene - the same phenotypes for different genes - one phenotype
some mutations
- a different phenotype for
other mutations
different phenotype
t Gene I Gene ll Gene lI
-- " * * * * H'---F or I or 1
Same phenotype Same phenotype
• mutation
27. See supra discussion accompanying note 1.
28. See GELEHRTER ET AL., supra note 13, at 4, 23-42 ("We define Mendelian diseases as
diseases that are the result of a single mutant gene that has a large effect on phenotype and
that are inherited in simple patterns similar to or identical with those described by Mendel
for certain discrete characteristics in garden peas.").
29. See generally Ruth Hubbard & R. C. Lewontin, Pitfalls of Genetic Testing, 334 NEw
ENG.J. MED. 1192 (1996).
30. See GELEHRTER ET AL., supra note 13, at 28.
31. See Wolf, Identical Mutations and Phenotypic Variation, supra note 26, at 305, and Fig-
ure 1.
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"Allelic heterogeneity" refers to different mutations at one locus
(gene).32 It is rare that every patient will have the identical sequence
alteration (an exception is sickle cell anemia). More commonly,
many different mutations are identified. For example, since it was
cloned in 1989," 3 over 700 mutations have been identified in the cystic
fibrosis (CF) gene.34 Cystic fibrosis is "the most prevalent cause of
severe, progressive lung disease in children and has become an impor-
tant cause of lung-related morbidity and mortality in young adults." 5
The encoded protein, a chloride channel known as CFTR (cystic fi-
brosis transmembrane conductance regulator), plays a critical role as
a gatekeeper of salt and water transport in and out of cells which form
the lining of various organs including the lungs and the intestines. 6
Altered salt and water transport in the lungs of CF patients is associ-
ated with thick mucous secretions and recurrent infections which lead
to the destruction of lung tissues and respiratory failure. 7
The functional consequence of each particular mutation may
have a variable influence on the severity of the disease (phenotype).
In some cases, as with mutations in the CF gene, mutations can be
categorized based on the molecular defect." While all mutations re-
sult in reduced chloride channel function in some way, these classifi-
cations may have a significant impact on the avenue of research that is
pursued and importantly, may dictate different treatment strategies
based on genotype.39 It may be insightful to compare the different
classes of mutations in CFTR to various breakdowns of a bicycle to
illustrate the value of genotype (i.e., mutation specific) based thera-
pies (Table 1).
32. See GELEHRTER ET AL., supra note 13, at 28.
33. SeeJohn R. Riordan et al., Identification of the Cystic Fibrosis Gene: Cloning and Charac-
terization of Complementary DNA, 245 SCIENCE 1066, 1066 (1989).
34. See Cystic Fibrosis Mutation Data Base (last modified Apr. 6, 1998) <http://
www.genet.sickkids.on.ca/cftr/mutations.html> (listing all currently identified mutations
in cystic fibrosis transmembrane conductance regulator).
35. MichaelJ. Welsh et al., Cystic Fibrosis in 3 THE METABOLIC AND MOLECULAR BASES OF
INHERITED DISEASE 3799, 3800 (Charles R. Scriver et al., eds., 7th ed. 1995).
36. See id. at 3799.
37. See id.
38. See generally MichaelJ. Welsh & Alan E. Smith, Molecular Mechanisms of CFTR Chloride
Channel Dysfunction in Cystic Fibrosis, 73 CELL 1251 (1993).
39. See id. at 1253.
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TABLE I: COMPARISON OF THE CONSEQUENCES OF A DEFECT IN A
PROTEIN (CFTR) WITH THOSE OF A BICYCLE
Class CFIR defect Analogous bicycle defect
I PROTEIN PRODUCTION The bike is held up in(construction of the production at the factory
protein within the cell) because the instruction
manual for assembly is
incomplete.
II PROCESSING The handlebars are too
(delivery of the protein to wide and protrude through
the surface of the cell) the shipping box. The box
is held up at the shipping
warehouse for safety
reasons.
III GATING The brakes are adjusted
(opening and closing of too tightly4 °
the channel)
IV CONDUCTION The bike is stuck in low
(rate of throughput of the gear.
channel)
Assembly and delivery turn out to be formidable barriers within a
cell for proteins involved in cystic fibrosis, breast cancer, and colon
cancer. The crucial message here is that there is no value in having
the tools to fix the brakes or the gears if the bike is stuck in the
warehouse.
In contrast to disease-causing mutations, common sequence vari-
ations, most with absolutely no phenotypic consequences, occur on
the average every 1000 base pairs. Continuing with the analogy, if the
bicycle was painted a different color, it would still function properly.
Sequence variation, which is observed just as often in individuals who
do not exhibit disease as in those who do, is referred to as a polymor-
phism. Sometimes distinguishing a polymorphism from a disease mu-
tation is not so easy, however. A gold-standard determination can
come from a functional assay,4 ' but such assays are not currently avail-
able for many disease genes, since their function remains unknown.
40. The antithesis of cystic fibrosis is secretory diarrhea, as caused by the cholera toxin,
in which an individual suffers from dehydration due to excessive secretion of salt and water
in the intestines. See id at 1252. This is analogous in the bicycle comparison to having no
brakes at all. See id.
41. Cellular machinery converts a gene (blueprint) into a protein. Each protein per-
forms one or more tasks, or functions. "Functional assays" are methods which are devel-
[VOL. 1:329
IMPLICATIONS OF THE GENETIC REVOLUTION
The second classification of genetic heterogeneity is locus heteroge-
neity. This refers to the fact that, for many diseases, more than one
gene can be involved in disease onset. For example, inherited breast
cancer has been associated with mutations in nearly a dozen genes
(albeit to varying levels of risk), and the list is unlikely to be com-
plete.42 These genes include BRCA1, 43 BRCA2,44 p5345 and PTEN/
MMAC1. 46 Inherited mutations in BRCA1 and BRCA2 may account
for as many as 5-10% of all breast cancer cases in the general popula-
tion.47 The epidemiological features of inherited, or familial breast
cancer which distinguish it from spontaneous (non-inherited) cases
are: (1) a strong family history of breast cancer in most cases, (2)
early onset of the disease, and (3) the occurrence of other cancers in
addition to breast cancer.48
In the context of attempting to assess an individual's risk of dis-
ease, allelic and locus heterogeneity create a major technological
problem for they necessitate screening one or more potentially large
genes rapidly and accurately for all possible heterozygous mutations.49
Current technologies often detect only a finite set of previously de-
fined mutations. Efforts to screen an entire gene using these methods
would be tedious and not very cost-effective. The emergence of DNA
chip-based technology, 50 however, may provide a valuable new tool for
high-throughput cost-efficient detection of genetic alterations. 51 Ap-
oped to measure the function of the protein, ideally in a quantitative manner. Such assays
are often critical to determining the consequences of mutations in the gene.
42. See generally Mark H. Greene, Genetics of Breast Cancer, 72 MAYo CLINICAL PROC. 54
(1997) (discussing clues to inheritable forms of cancer and the mapping of inherited can-
cer genes); Fearon, supra note 26.
43. See Yoshio Miki et al., A Strong Candidate for the Breast and Ovarian Cancer Susceptibility
Gene BRCAI, 266 SCIENCE 66 (1994).
44. See Richard Wooster et al., Identification of the Breast Cancer Susceptibility Gene BRCA2,
378 NATURE 789, 790 (1995).
45. See David Malkin et al., Germ Line p53 Mutations in a Familial Syndrome of Breast Can-
cer, Sarcomas, and Other Neoplasms, 250 SCIENCE 1233, 1234 (1990).
46. See generally Peter A. Steck et al., Identification of a Candidate Tumor Suppressor Gene,
MMAC1, at Chromosome 10q23 .3 that is Mutated in Multiple Advanced Cancers, 15 NATURE GE-
NETICS 356, 361 (1997).
47. See Lawrence C. Brody & Barbara Bowles Biesecker, Breast Cancer: The High-Risk
Mutations, 32 Hosp. PRAc. 59, 59 (1997).
48. See generally Greene, supra note 42, at 55.
49. See generallyJoseph G. Hacia et al., Detection of Heterozygous Mutations in BRCAI Using
High Density Oligonucleotide Arrays and Two-Colour Fluorescence Analysis, 14 NATURE GENETICS
441 (1996).
50. See generally Graham Ramsey, DNA Chips: State-of-the Art, 16 NATURE BIOTECHNOLOGY
40 (1998).
51. See Mark Chee et al., Accessing Genetic Information with High-Density DNA Arrays, 274
SCIENCE 610, 610-13 (1996); Ann C. Pease et al., Light-Generated Oligonuceotide Arrays for
Rapid DNA Sequence Analysis, 91 PROC. NAT'L ACAD. Sci. USA 5022, 5022-26 (1994).
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plications to mutation detection in BRCA1,5 2 CFTR,5 3 and HIV54 have
already proven feasible in the research laboratory, though issues of
sensitivity, specificity, and cost must be further explored.
Another concept that is fundamental to understanding the pro-
cess of predictive genetic testing is that of penetrance, which is "an all-
or-none phenomenon that refers to the clinical expression, or lack of
it, of the mutant gene."5 5 This vital concept in discussions of pre-
symptomatic genetic testing addresses the likelihood that a given se-
quence alteration will actually result in disease. For an individual, the
probability of acquiring the disease being tested for is either 100% or
0% (i.e., either they will or will not get the disease). Yet penetrance
estimates are, by necessity, statistical, and are most often based on
high-risk family or population studies. Estimated risks may vary signif-
icafntly depending on which segment of the population was examined.
Some genetic alterations, such as those in the gene causing Hunting-
ton's disease (HD), are 100% penetrant5 6 - if an individual lives long
enough, the disease will be expressed. It is critical to realize that, in
contrast to classical Mendelian disorders such as Huntington's dis-
ease, Tay Sachs, or cystic fibrosis, this level of predictive capacity in the
context of multifactorial disease (which affect an overwhelmingly
greater proportion of the general population and therefore will ac-
count for the majority of genetic tests in the future) will most likely be
exceedingly rare due to the low penetrance of any individual
mutation.
The penetrance of BRCA1 and BRCA2 mutations is currently the
subject of controversy.5 7 Initial estimates, based on studies of high-
risk families calculated a 76-87% risk of breast cancer for carriers of
genetic mutations in BRCA1.58 Epidemiologists have rightly been cau-
tious about risk estimates based on selective data sets such as those
comprised of high-risk families. A more recent study examined sam-
ples from a population of more than 5000 AshkenaziJews and found a
52. See generally Hacia et al., supra note 49, at 441.
53. See generally Maureen T. Cronin et al., Cystic Fibrosis Mutation Detection by Hybridiza-
tion to Light-Generated DNA Probe Arrays, 7 HUM. MUTATION 244 (1996).
54. See generally Michael J. Kozal et al., Extensive Polymorphisms Observed in HIV-1 Clade B
Protease Gene Using High-Density Oligonucleotide Arrays, 2 NAT. MED. 753 (1996).
55. See GELEHRTER ET AL., supra note 13, at 27.
56. See id. at 27.
57. See, e.g., Doug Easton, Breast Cancer Genes-What Are the Real Risks?, 16 NATURE GE-
NETICS 210 (1997).
58. See Doug F. Easton et al., Breast and Ovarian Cancer Incidence in BRCA1-Mutation
Carriers, 56 AM. J. HUM. GENETICS 265, 270 (1995).
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significantly lower value of breast cancer penetrance, 56%, for three
specific BRCA1 or BRCA2 mutations."
Whether the penetrance estimate provided to a woman who
tested positive for a BRCA1 or BRCA2 mutation is 56% or 87%, it
nonetheless raises a multitude of complex and difficult decisions. As
discussed in an editorial in the New England Journal of Medicine by for-
mer NIH director Bernadine Healy,
one of the effects of the discovery of the BRCA genes is the
emergence of medical bookmaking and fortunetelling ....
[Recent] reports should alert us to the limitations of the ex-
panding medical practice of making gene-based statistical
prophecies. The problem is not that the evolving informa-
tion is not valuable,6" but, rather, that it holds great potential
for misapplication.61
Added to the uncertainty of the risk, is the "paucity of data to guide
physicians in making follow-up recommendations to those who are
found to be carrying a mutation."6 2 For example, while preventive
strategies in high-risk individuals make intuitive sense, there is as yet
little definitive evidence that increased surveillance (mammography)
or prophylactic mastectomy will prevent ultimate death from breast
cancer63 in these high-risk women. "Information about the value of a
preemptive strike against cancer in carriers of BRCA mutations is at
best primitive . ,,64 This dictates that those considering testing un-
derstand the implications of both a positive or negative test result
through a process of education and informed consent before testing.
More research into testing decisions and their outcome is greatly
needed.65
Predictive genetic testing for colon cancer may offer greater
clinical utility because there is stronger evidence that increased sur-
59. See Jeffrey P. Struewing et al., The Risk of Cancer Associated with Specific Mutations of
BRCA1 and BRCA2 among AshkenaziJews, 336 NEw ENG.J. MED. 1401, 1401-02, 1407 (1997).
60. See Greene, supra note 42, at 62.
61. Bernadine Healy, BRCA Genes-Bookmaking, Fortunetelling, and Medical Care, 336
NEW ENG. J. MED. 1448, 1448 (1997).
62. Barbara Bowles Biesecker & Lawrence C. Brody, Genetic Susceptibility Testing for
Breast and Ovarian Cancer: A Progress Report, 52J. AM. ME). WOMEN'S Ass'N 22, 22 (1997).
63. See Deborah Schrag et al., Decision Analysis-Effects of Prophylactic Mastectomy and Oo-
phorectomy on Life Expectancy Among Women with BRCA 1 or BRCA2 Mutations, 336 NEw ENG. J.
MED. 1465, 1470 (1997).
64. Healy, supra note 61, at 1448.
65. See Biesecker & Brody, supra note 62, at 22.
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veillance and early detection are associated with improved outcome."
Already genetic testing for familial polyposis and hereditary non-poly-
posis colon cancer (HNPCC) has many advocates. 67 A recent report 68
identifies a sequence alteration in the adenomatous polyposis coli
(APC) gene which is associated with an estimated twofold increase risk
of colon cancer and occurs with high frequency (6%) in the
Ashkenazi Jewish population, making it potentially the most common
cancer-associated mutation known in a specific population. Large
population-based studies are underway.69 The results may have signif-
icant implications for large-scale screening recommendations.
It is anticipated that the majority of future genetic discoveries will
involve sequence alterations with even lower penetrance values than
that realized for BRCA1 or BRCA2. Genes which play a role in com-
plex diseases such as heart disease, hypertension, diabetes, and psychi-
atric disorders will be identified, but the alleles associated with
increased risk may each only confer a modest effect.
II. THE HuMAN GENOME PROJECT: BEYOND THE
SCIENTIFIC CONCERNS
The designers of the HGP, in particular Dr. James Watson, 70 rec-
ognized that the information gained from mapping and sequencing
the human genome would have profound implications for individuals,
families, and society. To address the complex issues which arise from
human genetics research, the Ethical, Legal and Social Implications
(ELSI) Program was established from the onset as an integral part of
the HGP.7'
66. See generally Wylie Burke et al., Recommendations for Follow-up Care of Individuals with
an Inherited Predisposition to Cancer, I: Hereditary Nonpolyposis Colon Cancer 277 JAMA 915
(1997).
67. See generally id.
68. See Steven J. Laken et al., Familial Colorectal Cancer in Ashkenazim Due to a
Hypermutable Tract in APC, 17 NATURE GENETICS 79 (1997).
69. Personal conversation with Lawrence C. Brody, Investigator, Genetics and Molecu-
lar Biology Branch, National Human Genome Research Institute (Feb. 2, 1998).
70. Dr. Watson was the first Director of the Human Genome Project from 1989 to 1992
and winner of the Nobel Prize for codiscovering the double-helical structure of DNA in
1953. See Interview with James D. Watson (Oct. 22, 1991) available at Dr. James D. Watson
(visited Apr. 10, 1998) <http.www.achievement.org/autodoc/page/wat0int-l>.
71. See Eric M. Meslin et al., The Ethical Legal, and Social Implication Research Program at
the National Human Genome Research Institute, 7 KENNEDY INST. ETHICS J. 291 (1997). De-
tailed information about the ELSI program can also be found at their web site. See About the
Ethical, Legal, and Social Implications of Human Genetics Research Program (last modified Oct.,
1997) <http://-,vw.nhgri.nih.gov/ELSI/aboutels.html#"Ahatis>.
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As the ELSI Program has evolved, four high priority areas of
focus for research and policy activities have emerged:
1. Privacy and Fairness in the Use and Interpretation of Ge-
netic Information. Activities in this area examine the mean-
ing of genetic information and how to prevent its
misinterpretation or misuse,
2. Clinical Integration of New Genetic Technologies. These
activities examine the impact of genetic testing on individu-
als, families and society and inform clinical policies related
to genetic testing and counseling,
3. Issues Surrounding Genetics Research. Activities in this
area focus on informed consent and other ethical issues re-
lated to the design, conduct, participation in and reporting
of genetics research,
4. Public and Professional Education. This area includes ac-
tivities that provide education on genetics and related ELSI
issues to health professionals, policy makers and the general
public.7 2
The Office of Policy Coordination (OPC) at NHGRI in conjunc-
tion with the ELSI Working Group, breast cancer advocates, and other
consumer groups, has been focusing efforts on what we view as the
two pillars of protection necessary to prevent the misuse of genetic
information. The first pillar consists of the enactment of anti-discrim-
ination laws, especially in the realm of health insurance and employ-
ment, and the second focuses on the assurance of privacy protections
for individuals involved in genetic testing.
As mentioned previously, each of us has an estimated five to fifty
serious misspellings or alterations in our DNA; thus, we could all be
targets for discrimination based on our genes. The authors see this as
fundamentally a civil rights issue.7" No one gets to choose their DNA,
and the DNA that we inherit is immutable. Policies that allow genetic
information to be used to discriminate against individuals, families or
groups are unjust. Of particular concern is the fear of losing jobs or
health insurance because of a particular predisposition to a particular
disease. These are already real concerns for many Americans. In a
recent survey of people in families with genetic disorders, 22% indi-
72. See Meslin et al., supra note 71; see also ELSI website (last modified Oct., 1997)
<http://www.nhgri.nih.gov/ELSI/aboutels.httmt # Issue>.
73. See Francis S. Collins, Presentation at Inaugural Meeting of the National Bioethics
Advisory Commission (NBAC) (Oct. 4, 1996) (transcripts on file with the author and at the
NBAC web site (visited Jan. 14, 1998) <http://www.nih.gov/nbac/
minutes100496pm.htm>).
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cated that they, or a member of their family, had been refused health
insurance on the basis of their genetic information."4 The over-
whelming majority of those surveyed felt that health insurers should
not have access to genetic information.75 A 1995 Harris poll of the
general public found a similar level of concern.76 Over 85% of those
surveyed indicated they were very concerned or somewhat concerned
that insurers or employers might have access to and use genetic
information.77
Discrimination in health insurance, and the fear of potential dis-
crimination, threaten both society's ability to use new genetic technol-
ogies to improve human health and the ability to conduct the very
research we need to understand, treat, and prevent genetic disease.
To unravel the basis of complex disorders, scientists must analyze the
DNA of many hundreds of people for each disease they study. Thus
valid research on complex disorders will require the participation of
large numbers of volunteers. But a pall of mistrust hangs over re-
search programs because study volunteers are concerned that their
genetic information will be used by insurers to discriminate against
them.78
There has been recent debate about how pervasive genetic dis-
crimination actually is. Whether these fears are real or perceived,
they clearly have had a negative impact on the ability of genetic re-
searchers to find participants for their studies.7' For example, "[i]n
genetic testing studies at the NIH, nearly one third of eligible people
offered a test for breast cancer risk decline to take it. The overwhelm-
ing majority of those who refuse, cite concerns about health insurance
discrimination and loss of privacy as the reason."' There is little disa-
74. See E. Virginia Lapham et al., Genetic Discrimination: Perspectives of Consumers, 274
SCIENCE 621, 622 (1996).
75. See id.
76. See Sam Greengard, Genetic Testing: Should you be afraid? It's No Joke, 76 PERSONNEL J.
38 (1997) available in 1997 WL 12291208 (citing to a 1995 Harris Poll finding that 86% of
1000 respondents felt insurers may use genetic test results as a basis for decision-making).
77. See id.
78. See Geoffrey Cowley, Flunk the Gene Test and Lose Your Insurance, NEWSWEEK, Dec. 23,
1996, at 48.
79. Barbara L. Weber & Kathleen Calzone, Remarks at the Privacy Planning Meeting of
NHGRI-NAPBC (June 9, 1997); see Dorothy Wertz, How Many People Seek Genetic Testing for
Cystic Fibrosis, BRCA1, and Huntington Disease, 1 GENE LETrER 1 (1997); Eliot Marshall, Gene
Tests Get Tested, 275 SCIENCE 782 (1997).
80. See Francis S. Collins, Statement before the Congressional Task Force on Health
Records and Genetic Privacy, Preventing Genetic Discrimination in Health Insurance (July 22,
1997) (transcript available with author and on the web site for the National Human Gen-
ome Research Institute at the National Institutes of Health (visited Feb. 6, 1998) <http://
www.nhgri.nih.gov/Policy-and-public-affairs/Legislation/stearnsh.html>).
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greement that there is a paucity of scientific data to address this issue
and that obtaining accurate numbers will be difficult. It is important
to realize, however, that while most people have not yet undergone
genetic testing, with recent discoveries and a market increasingly
driven by commercial interests, a rapid change in the near future is
anticipated. Hopefully, it will not be necessary to wait until large
numbers of individuals are injured by discrimination before legal and
policy protections are put in place. Whether the incidence of discrim-
ination is less than 1%, greater than 10%, or somewhere in between,
efforts should be directed at preventing such misuse of genetic infor-
mation based simply on the principle that unfair discrimination is
wrong. Efforts to enact protective legislation must be based on princi-
ples and must not be deterred by debates over numbers and
percentages.
The most substantial progress has been made in efforts to protect
individuals from unfair discrimination in health insurance. The NIH-
DOE ELSI Working Group and NAPBC jointly developed a series of
recommendations for state and federal policy-makers which were pub-
lished in 1995." These recommendations state that:
1. Insurance providers should be prohibited from using ge-
netic information, or an individual's request for genetic
services, to deny or limit any coverage or establish eligi-
bility, continuation, enrollment, or contribution
requirements.
2. Insurance providers should be prohibited from establish-
ing differential rates or premium payments based on ge-
netic information or an individual's request for genetic
services.
3. Insurance providers should be prohibited from request-
ing or requiring collection or disclosure of genetic
information.
4. Insurance providers and other holders of genetic infor-
mation should be prohibited from releasing genetic in-
formation without prior written authorization of the
individual. Written authorization should be required for
each disclosure and include to whom the disclosure
would be made.8 2
81. See Kathy L. Hudson et al., Genetic Discrimination and Health Insurance: An Urgent Need
for Reform, 270 SCIENCE 391, 393 (1995).
82. See id.
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The Health Insurance Portability and Accountability Act of 1996
(HIPAA) s3 was a landmark piece of federal legislation for genetics.
The bill prohibits health insurers from using genetic information to
deny or limit health insurance coverage to members of group plans.84
However, it does not prohibit rate increases as a consequence of ge-
netic test results, nor does it adequately protect individuals who are
not in a group plan, thus leaving serious gaps in efforts to prevent
genetic discrimination by insurance companies.8 5 Since none of us
can be assured that we will not need individual coverage in the future,
and genetic information about us is permanent, the protections pro-
vided by HIPAA are not sufficient. A number of states have enacted
legislation regarding genetic information and health insurance, 6 but
as yet no fully comprehensive federal laws are in place.8 7 There have
been a number of additional pieces of federal legislation proposed
during the 104th and 105th Congresses 8 and the President of the
United States announced his support for closing the remaining loop-
holes in July 1997.89
In addition to the efforts put forth to address health insurance
issues, the NIH-DOE ELSI Working Group and NAPBC also worked
together to jointly develop a series of policy recommendations to pre-
vent unfair discrimination in the workplace.90 There are parallel rec-
ommendations aimed to prevent misuse of genetic information in
both of these realms, but there is a possible difference in at least one
respect in the context of the workplace. 1 Because it is much more
difficult to prove that a prospective or current employee was discrimi-
nated against based on genetic information, it is perhaps more critical
83. See Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-
191 110 Stat. 1936 (1996).
84. See id. § 9802(F).
85. SeeJeffrey Fox, Forget Washington: State Laws Threaten to Restrict Genetic Research, Too, 9
J. NIH RESEARCH 19 (1997).
86. Karen H. Rothenberg, Genetic Information and Health Insurance: State Legislative Ap-
proaches, 23J.L. MED. ETHICS 312, 312-19 (1995).
87. See Hudson et al., supra note 81, at 392.
88. See, e.g., H.R. 306, 105th Cong. (1997); H.R. 328, 105th Cong. (1997); S. 89, 105th
Cong. (1997); S. 1600, 104th Cong. (1996); S. 1416, 104th Cong. (1995); H.R. 2690, 104th
Cong. (1996). A comprehensive list of these proposed bills (including text, cosponsors
and legislative history) can be found at the NHGRI web site (visitedJan. 14, 1998) <http:/
/www.nhgri.nih.gov/Policy-and-public-affairs/Legislation/fedlegis.html#dlegis>.
89. President William Jefferson Clinton, Remarks at the Genetic Screening Event (July
14, 1997) (transcripts available at the 'White House Virtual Library' web site (visited Jan.
14, 1998) <http://library.whitehouse.gov/> by searching the "White House documents"
site using the phrase "genetic" and the date "July 14, 1997").
90. See Karen Rothenberg et al., Genetic Information and The Workplace: Legislative Ap-
proaches and Policy Changes, 275 SCIENCE 1755, 1755-57 (1997).
91. See id. at 1756.
[VOL. 1:329
IMPLICATIONS OF THE GENETIC REVOLUTION
to incorporate limited access to this information by employers.92
Therefore, this effort requires stricter attention to privacy issues. 93
In 1997, recommendations for state and federal policy-makers re-
garding the prevention of misuse of genetic information in the work-
place were published by the Hereditary Susceptibility Working Group
of the NAPBC and the ELSI Working Group.94 These recommenda-
tions are aimed at preventing the access and use of genetic informa-
tion by employment organizations unless the information can be
proven to be 'job related and consistent with business necessity."95
Currently, "[e]mployers in most jurisdictions are not prohibited from
requiring genetic testing, even though there is insufficient evidence to
justify the use of any existing test for genetic susceptibility96 [with the
possible exception of HLA testing of miners and machinists of beryl-
lium]97 as a basis for employment decisions."98 "Employers may be
reluctant to hire or promote individuals they believe will become pre-
maturely unable to work."99 Similar to the situation with health insur-
ance, no comprehensive federal law addresses genetic discrimination
in the workplace. However, "[iun 1995, the Equal Employment Op-
portunity Commission (EEOC) issued a guidance in its compliance
manual on the definition of 'disability' that addresses genetic discrimi-
nation in the workplace."'00 It stated that "the Americans with Disabil-
ities Act (ADA) would 'protect individuals subjected to discrimination
on the basis of genetic predisposition,' because in that situation the
employer would be regarding the employee as disabled."'' In addi-
tion, a number of states have enacted laws that address the issue.10 2
92. See id.
93. See id.
94. See id at 1755.
95. Id. at 1756.
96. Id. at 1755.
97. See Luca Richeldi et al., Interaction of Genetic and Exposure Factors in the Prevalence of
Berylliosis, 32 AM.J. INDUSTRIAL MED. 337, 338-40 (1997); see Luca Richeldi et al., HLA-DPBI
Glutamate 69: A Genetic Marker of Beryllium Disease, 262 SCIENCE 242, 242-44 (1993).
98. Rothenberg, supra note 90, at 1755.
99. Council on Ethical and Judicial Affairs, American Medical Association, Use of Genetic
Testing by Employers, 266 JAMA 1827, 1827 (1991).
100. Rothenberg, supra note 90, at 1756 (citing EQUAL EMPLOYMENT OPPORTUNrIY COM-
MISSION COMPLIANCE MANUAL, vol. 2, § 902, Order 915.002, 902-45 (1995) [hereinafter
COMPLIANCE MANUAL]).
101. Rothenberg, supra note 90, at 1756 (quoting COMPLIANCE MANUAL, supra note 90 at
902-45).
102. See Rothenberg, supra note 90, at 1755-56. For example, Wisconsin and several
other states have prohibited genetic testing of employees without informed consent,
barred discrimination based on the results of genetic testing, and criminalized disclosure
of test results without the employee's consent. See id. at 1755. New Jersey focuses more
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The task of affording federal protection for the privacy of an indi-
vidual's genetic information is perhaps the greatest challenge, given
the inherent complexity of privacy legislation/regulation, in general,
and the involvement of many more stakeholders than in the health
insurance and employment anti-discrimination arena. The issue of
privacy of genetic information is embedded in the larger context of
medical records privacy, as most experts agree that any effort to sepa-
rate the two will be intellectually impossible."' 3 Federal law currently
does not adequately protect the confidentiality of medical informa-
tion."°4 "In fact, video rental records are afforded more federal pro-
tection than are medical records."'1 5  Language in HIPAA,' 06
however, directed that progress must be made in the near future. The
result of that directive was a report which was submitted to Congress
last fall by the Department of Health and Human Services (HHS) Sec-
retary Donna I. Shalala.10 7 The report provided "recommendations
for federal health record confidentiality legislation that would guaran-
tee rights for patients and define responsibilities for record keepers,
so that there will be clear guidance and real incentives for confiden-
tial, fair, and respectful treatment of personal health information, and
penalties for its misuse. '' 18 Absent from these recommendations pro-
posed by the HHS Secretary, however, was guidance for the protection
of information generated or obtained in the course of research.
broadly on prohibiting the use of genetic information, including phenotype indicators and
family history. See id. at 1756.
103. See NIH WORKING GROUP ON ETHICAL, LEGAL, AND SOCIAL IMPLICATIONS OF HUMAN
GENOME RESEARCH, GENETIC INFORMATION AND HEALTH INSURANCE 13 (NIH Publication
No. 93-3686, 1993).
104. Federal law does protect "records relating to substance abuse or records in the
custody of the federal government." Sheri Alpert, Smart Cards, Smarter Policy: Medical
Records, Privacy, and Health Care Reform, 23 HASTINGS CENTER REP. 13 (1993). This paper
also discusses the fact that some states recognize a provider-patient privilege and have spe-
cific laws to deal with highly sensitive medical information such as mental health records
and/or AIDS test results. See id.
105. Id. at 13 (citing Pub. L. No. 100-618).
106. Health Insurance Portability and Accountability Act, Pub. L. No. 104-191, § 264,
110 Stat. 1936, 2033 (1996). This section on administrative simplification directed the
Secretary of Health and Human Services (HHS) to promulgate regulations for "standards
with respect to the privacy of individually identifiable health information" by August 21,
1997. Id.
107. See SECRETARY OF HEALTH AND HUmAN SERVICES, CONFIDENTIALITY OF INDIVIDUALLY-
IDENTIFIABLE HEALTH INFORMATION 1997. The entire text of the report can also be found
at the HHS web site (visited Feb. 6, 1998) <http://aspe.os.hhs.gov/admnsimp/
pvcrec0.htm>.
108. HHS Press Office, Shalala Urges Congress to Protect Americans'Personal Medical Record
(visited Jan. 14, 1998) <http://www.hhs.gov/news/press/1997pres/97091 lc.html>.
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Efforts at NHGRI have focused on the need for privacy and confi-
dentiality safeguards in genetic research, as it has become increasing
clear that participation in such research has been negatively affected
by fear of the loss of privacy of genetic information by potential par-
ticipants. A background paper was drafted.. 9 and a workshop con-
vened in September 1997 to bring together experts from a variety of
disciplines. The goal was to assess current policies, ascertain varied
viewpoints, stimulate dialogue between diverse and sometimes adver-
sarial parties, and to identify areas where new or modified policies or
practices might enhance privacy protection and promote the conduct
of important biomedical research. It is expected that the outcome
from that workshop will be the development and publication of a set
of policy recommendation for researchers, research institutions, agen-
cies, and/or Congress.
A. The Future of Medicine
Undoubtedly, the future will find predictive genetic testing avail-
able for a large number of disorders, including many with low pene-
trance. Patients will benefit from these test results in a number of
significant ways. Information derived from these tests will allow indi-
vidualized gene-based preventive medicine. Ultimately, the identifica-
tion of the molecular basis of disease will allow for the development of
gene-based therapies which have the potential to revolutionize the
practice of medicine and save many lives. But a number of barriers
threaten to limit the full medical benefit of the genetic revolution. It
would be a serious mistake to assume that the only remaining barriers
are technical and scientific ones, such as, improving mutation detec-
tion technologies or increasing the predictive accuracy of genetic test-
ing for predisposing genes. The first barrier is the fear of
discrimination as we have extensively discussed. Financial barriers are
also of great concern. Commercial tests are expensive and the willing-
ness of insurance companies to provide coverage is uncertain. Third,
cultural barriers may exist. For example, the discrimination exper-
ienced by African-Americans as a result of sickle cell screening pro-
grams in the 1970's has had an understandably lasting effect on their
willingness to embrace genetic testing.11 ° Similarly, the Ashkenazi
109. See Kathy Hudson et al., Privacy and Confidentiality in Genetics Research, 20
(1997) (unpublished draft on file with author).
110. SeeJAMES BOWMAN & ROBERT F. MURRAY, JR., GENETIC VARIATION AND DISORDERS IN
PEOPLES OF AFRICAN ORIGIN 365-66 (1990); see also generally Patricia A. King, The Past as
Prologue: Race, Class, and Gene Discrimination in GENE MAPPING: USING LAW AND ETHICS AS
GUIDES 94 (George J. Annas & Sherman Elias eds., 1992).
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Jewish population is very concerned that they may be subject to in-
creased levels of discrimination and social stigmatization111 due to the
misinterpretation of recent genetic research studies. 12 Finally, educa-
tional barriers for medical and health professionals and the general
public alike are potentially severe. Comprehending genetic informa-
tion is rarely straightforward and demands knowledgeable medical
and health professionals who thoroughly understand the appropriate
use and limitations of genetic tests, and who can effectively translate
this complex information to their patients. Our hope is that the fu-
ture will see the general public conversant in the fundamental of prin-
ciples of genetics and genetic disease. This would help to reduce the
overwhelming quantity of information which most individuals now are
forced to deal with for the first time during times of crisis - for exam-
ple during prenatal testing or diagnosis of cancer. Incorporating a
vocabulary of genetics into the vernacular will allow individuals to fo-
cus on the medical and psychosocial aspects of the information
provided.
B. Use of Predictive Genetic Information in the Courts
The possible incorporation of predictive genetic information into
decisions by the courts in cases, for example, of child custody, adop-
tion, property disposition, and personal responsibility for criminal
acts," 3 is a disturbing prospect to scientists who never imagined such
an application of this information. This troublesome scenario could
be prevented before ever reaching juries. The recent unanimous
Supreme Court decision in the case of General Electric v. Joiner"4 be-
stowed upon trial judges great discretion to decide what type of scien-
tific testimony can be presented to juries and was consistent with the
Daubert"5 rule which assigned judges the role of "gatekeepers. "116 We
welcome the exhortation by Justice Stephen G. Breyer in his concur-
111. See Sally Lehrman, Jewish Leaders Seek Genetic Guidelines, 389 NATURE 322 (1997); see
also Rick Weiss, Discovery of Jewish' Cancer Gene Raises Fears of More Than Disease, WASH. POST,
Sept. 3, 1997, at A3.
112. See Steven J. Laken et al., Familial Colorectal Cancer in Ashkenazim Due to a
Hypermutable Tract in APC, 17 NATURE GENETICS 79 (1997); see alsoJeffrey P. Struewing et
al., The Carrier Frequency of the BRCAI 185delAG Mutation Is Approximately 1 Percent in
Ashkenazi Jewish Individuals, 1 NATURE GENETICS 198 (1995).
113. Judge Rosalyn B. Bell, Remarks at the "NAPBC-NHGRI Workshop on Privacy and
Confidentiality in Genetics Research" (Sept. 16, 1997); Judge Rosalyn B. Bell, Remarks at
the University of Maryland School of Law workshop "Testing and Telling?: Implications for
Genetic Privacy, Family Disclosure and the Law" (Oct. 8, 1997).
114. 118 S.Ct. 512 (1997).
115. Daubert v. Merrell Dow Pharmaceuticals, 509 U.S. 579 (1993).
116. joiner, 118 S.Ct. at 520.
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ring opinion to encourage cooperation between the legal and scien-
tific communities.117 The efforts of the Einstein Institute for Science,
Health, and the Courts (EINSHAC) 118 to develop a series of confer-
ences for judges on cases involving genetics and molecular biology 19
are an important step in the right direction toward improved commu-
nication and cooperation.
We believe that it would be a significant error to use an individ-
ual's or family's genetic sequence information in a legal context to
confer either an advantage or disadvantage in such matters. The use
of this information in the courts is likely to be misleading on two
counts. The first is based on the scientific fact that in most cases,
there will not be sufficient precision in the genetic information tojus-
tify basing crucial decisions on it. The increased risk figures that may
be presented by various 'expert' witnesses will be based on population
studies, yet the decisions to be made in the courtroom are about indi-
viduals. It would be highly unfortunate to have lawyers and judges
making decisions based on uncertain predictive genetic information,
or to ask juries to try to do so. After all, "research and discovery in the
first century of the next millennium will reduce the uncertainties, but
the nature of human variation is such that it will never be possible to
have genetic tests that are perfect predictors of disease."1 2°
However, there is a second reason not to use an individual's or
family's genetic sequence information in a legal context: to do so
would be an unfair form of discrimination.1 21 People do not get to
choose their own genes, nor can they change the genes they have
been given. This is a civil rights issue as much as are race and gender
discrimination. To base judgment on that which is inherited and im-
mutable is simply wrong.
117. See generally Stephen Breyer, The Interdependence of Science and Law, 280 SCIENCE 537
(1998).
118. "EINSHAC is a non-profit corporation . . . [established] in 1993. . . . [It] is a
research, technical assistance and education organization dedicated to assist courts man-
age scientific issues brought into complex litigation and prosecution." The Einstein Insti-
tute for Science, Health and the Courts, The Courts and Science Online Magazine, 1-2
(visited Apr. 8, 1998) <http://www.ornl.gov/courts/journal/describe.htm>.
119. See Honorable Pauline Newman et al., Genetics in the Courtroom: An Introduction, 36
JUDGES'J. 1 (1997).
120. See PROMOTING SAFE AND EFFECTIVE GENETIC TESTING, supra note 21, at 3.
121. This is a proper response to the argument that the courts already base decisions on
information that is less predictive than genetics.
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III. SUMMATION
The link between a sequence alteration in the genome of an indi-
vidual and the possibility of future disease is complex; However, the
stakes are too high to allow the ethical discussions and legal debates to
be held without demanding that they be based on a thorough under-
standing of the fundamental principles of genetics and the realities of
what science can (and cannot) offer. Concepts such as locus hetero-
geneity, penetrance, and genotype-specific therapies must be well-
grasped by all participants if the deliberations are to be meaningful
particularly because these concepts are vital to understanding the sci-
entific and medical value of the genetic information. The genetics
research community will continue to work to educate lawyers,
ethicists, policymakers, and others, and to ensure that an individual's
genetic information is kept private and will be used solely for the med-
ical benefit of the individual and society. The potential negative con-
sequences of the misuse of genetic information and the depth of the
impact it may have on the lives of individuals and their families de-
mand our commitment to these efforts.
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